12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

BioAlliance, Vestiq sales and marketing update

BioAlliance said Vestiq launched Oravig miconazole in the U.S. to treat oropharyngeal candidiasis. The wholesale acquisition cost is $254 for a 14-day...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >